Figure 4
Mebendazole has anti-leukemic activity both in vitro and in vivo. (a) Expression of CD11b, CD11c, and CD14 in primary human leukemia sample (SU674) as shown by flow cytometric analysis. The leukemia blasts were treated with mebendazole (1 μM) for seven days. (b) Morphology of primary human leukemia sample (SU674) as shown by Wright’s staining. The leukemia blasts were treated with mebendazole (1 μM) for nine days. Scale bar is 20 μm in length. (c) Changes of surface markers and cell morphologies of five primary AML leukemia samples treated with mebendazole. Data are presented as mean + standard deviation. (d) Survival of NSG mice with THP-1 leukemia xenografts treated with either mebendazole (n = 5, red line) or vehicle control (n = 6, grey line).
